New drug cocktail aims to boost pancreatic cancer surgery success
NCT ID NCT06587061
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resectable pancreatic cancer will receive the combination, then surgery, then more treatment. The study will measure safety, tumor response, and how many patients achieve complete tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4642 combined with gemcitabine and albumin-bound paclitaxel
What this could lead to
If successful, this could lead to a more effective pre- and post-surgery treatment for pancreatic cancer, potentially improving survival and surgical outcomes.
What could go wrong
This is an early Phase 2 trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact